NZE · OCA.NZ
Oceania Healthcare Limited
NZ$0.64-NZ$0.01 (-1.54%)
Oceania Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 31.18% below the high.
Loading market information…
NZE · AFT.NZ · NZD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NZD. Historical prices are not a forecast.
AFT Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
AFT Pharmaceuticals Limited’s forward annual dividend is NZ$0.02 per share, paid annual. The forward yield is 0.39% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow AFT Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health categories, including but not limited to allergy relief, cold and flu remedies, digestive health, eye care, first aid essentials, nail and oral care, pain management, skincare solutions, and nutritional supplements. This company was established in 1997 and its main office is located in Auckland, New Zealand.
Latest available per-share figures in NZD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NZ$86.71M-9.77% vs estimate |
| Q4 2023 | May 22, 2023 | NZ$0.09 | NZ$90.89M-17.82% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NZ$0.64-NZ$0.01 (-1.54%)
Oceania Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 31.18% below the high.
NZ$0.24NZ$0.00 (0.0%)
Pacific Edge Limited’s quoted price sits in the lower half of its reported 52-week range, 30.88% below the high.
NZ$1.93-NZ$0.01 (-0.26%)
Green Cross Health Limited’s quoted price sits in the upper half of its reported 52-week range, 14.22% below the high.
NZ$0.39NZ$0.00 (0.0%)
Radius Residential Care Limited’s quoted price sits in the lower half of its reported 52-week range, 20.41% below the high.
NZ$4.20-NZ$0.13 (-3.0%)
Third Age Health Services Limited’s quoted price sits in the lower half of its reported 52-week range, 43.78% below the high.
NZ$0.67NZ$0.00 (0.0%)
Promisia Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 15.19% below the high.
NZ$0.02-NZ$0.00 (-8.0%)
BLIS Technologies Limited’s quoted price sits in the upper half of its reported 52-week range, 25.81% below the high.
NZ$0.03NZ$0.00 (0.0%)
Rua Bioscience Limited’s quoted price sits in the lower half of its reported 52-week range, 38.1% below the high.